- ÀÛ¼ºÀÚ
- °ü¸®ÀÚ
- ÀÛ¼ºÀÏ
- 2018-09-12
- Á¶È¸
- 3100
´ëÇÑÇ÷¾×ÇÐȸ ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´ ¿¬±¸È¸ ½ÉÆ÷Áö¾öÀÌ ¾Æ·¡¿Í °°ÀÌ °³ÃֵǿÀ´Ï ȸ¿ø ¿©·¯ºÐµéÀÇ ¸¹Àº °ü½É°ú Âü¿© ºÎŹµå¸³´Ï´Ù.
= ¾Æ·¡ =
ÀϽÃ: 2018³â 11¿ù 17ÀÏ (Åä)
Àå¼Ò: ¼¿ï´ëÇб³ ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼¼ºÈ¯¿¬±¸È¦
ÁÖÃÖ: ´ëÇÑÇ÷¾×ÇÐȸ ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´ ¿¬±¸È¸
µî·Ïºñ: ¹«·á
µî·Ï: ÇöÀå ´çÀϵî·Ï!!
ÆòÁ¡: ´ëÇÑÀÇ»çÇùȸ 3Á¡, Ç÷¾×Á¾¾ç³»°úºÐ°úÀü¹®ÀÇ 3Á¡
Time |
Program |
Speakers |
10:00~10:50 |
Registration |
|
10:50~11:00 |
Opening remarks |
À̼® À§¿øÀå |
Session I: Toward Detecting High-risk ALL ÁÂÀå: °¡Å縯ÀÇ´ë À̼®, Àü³²ÀÇ´ë ¾ç´öȯ |
||
11:00~11:30 |
NGS-based MRD detection |
°æºÏÀÇ´ë ¹®ÁØÈ£ |
11:30~12:00 |
Philadelphia Chromosome-like ALL |
°¡Å縯ÀÇ´ë ±è¸í½Å |
12:00~12:30 |
Early T-cell Precursor ALL |
¿ï»êÀÇ´ë Á¶¿µ¿í |
12:30~14:00 |
Lunch and Coffee break |
|
Session II: Incorporation of Immunotherapies into Salvage/Frontline Treatments ÁÂÀå: °è¸í´ë µµ¿µ·Ï, ºÎ»ê´ë ½ÅÈ£Áø |
||
14:00~14:30 |
Anti-CD19 Bispecific T-cell Engager: Blinatumomab |
ÀÎÁ¦ÀÇ´ë ÀÌ¿ø½Ä |
14:30~15:00 |
Anti-CD22 Ab-Drug Conjugate: Inotuzumab Ozogomicin |
°¡Å縯ÀÇ´ë À±ÀçÈ£ |
15:00~15:30 |
Updates on CAR T-cell Therapies |
Àü³²ÀÇ´ë Á¤¼ºÈÆ |
15:30~ |
Closing remarks |
À̼® À§¿øÀå |
´ëÇÑÇ÷¾×ÇÐȸ ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´ ¿¬±¸È¸ À§¿øÀå À̼® / °£»ç ¾ç´öȯ